• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苔藓样疹:口服克拉屈滨的一种新副作用。

Lichenoid rash: A new side effect of oral Cladribine.

机构信息

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples,Via Sergio Pansini, 580131 Naples Italy.

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples,Via Sergio Pansini, 580131 Naples Italy.

出版信息

Mult Scler Relat Disord. 2020 Jun;41:102023. doi: 10.1016/j.msard.2020.102023. Epub 2020 Feb 28.

DOI:10.1016/j.msard.2020.102023
PMID:32146431
Abstract

Cladribine is an approved drug for the treatment of highly active multiple sclerosis. We report a 28-years-old man with a poor response to previous treatments, elected to treatment with Cladribine. He developed a lichenoid rash two weeks after taking the first and second treatment cycles. This symptom regressed with specific therapy. A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications, but it has never been described after treatment with oral Cladribine.

摘要

克拉屈滨是一种已被批准用于治疗活跃性多发性硬化症的药物。我们报告了一例 28 岁的男性患者,他对以前的治疗反应不佳,选择接受克拉屈滨治疗。他在服用第一个和第二个治疗周期后两周出现了苔藓样皮疹。该症状在特定治疗后消退。苔藓样药疹是一种罕见的副作用,可能发生在使用几种不同药物后,但从未在口服克拉屈滨治疗后描述过。

相似文献

1
Lichenoid rash: A new side effect of oral Cladribine.苔藓样疹:口服克拉屈滨的一种新副作用。
Mult Scler Relat Disord. 2020 Jun;41:102023. doi: 10.1016/j.msard.2020.102023. Epub 2020 Feb 28.
2
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.在 cladribine 治疗后,多发性硬化症患者出现自身免疫性肾小球肾炎。
Mult Scler. 2021 Oct;27(12):1960-1964. doi: 10.1177/13524585211022719. Epub 2021 Jun 24.
3
An update on cladribine for relapsing-remitting multiple sclerosis.用于复发缓解型多发性硬化症的克拉屈滨最新进展
Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11.
4
Cladribine for multiple sclerosis.用于治疗多发性硬化症的克拉屈滨
Drug Ther Bull. 2018 Feb;56(2):21-24. doi: 10.1136/dtb.2018.2.0590.
5
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.克拉屈滨片治疗活跃复发型多发性硬化症患者的治疗满意度、安全性和耐受性:CLARIFY-MS 研究 6 个月中期分析。
Mult Scler Relat Disord. 2022 Jan;57:103385. doi: 10.1016/j.msard.2021.103385. Epub 2021 Nov 9.
6
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作,该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
7
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.多发性硬化症患者中克拉屈滨片剂的安全性和耐受性:CLARITY(CLAdRIbine Tablets treating multiple sclerosis orallY)研究。
Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12.
8
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].口服克拉屈滨治疗复发缓解型多发性硬化症:是另一种嘌呤类似物还是真正的治疗创新?
Nervenarzt. 2010 Oct;81(10):1231-41. doi: 10.1007/s00115-010-3040-6.
9
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.克拉屈滨片治疗多发性硬化症患者的安全性:综合分析。
Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.
10
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.在葡萄牙,克拉屈滨片与芬戈莫德治疗高度活跃复发型多发性硬化症的成本效益比较。
J Med Econ. 2020 May;23(5):484-491. doi: 10.1080/13696998.2020.1717499. Epub 2020 Feb 10.

引用本文的文献

1
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.高效多发性硬化症疗法对B细胞的影响。
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
2
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.真实世界研究中克拉屈滨片剂在多发性硬化症中的应用:疗效和安全性的进一步深入了解。
Wien Med Wochenschr. 2022 Nov;172(15-16):365-372. doi: 10.1007/s10354-022-00931-4. Epub 2022 Apr 22.
3
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.新型多发性硬化症疾病修正疗法的安全性
Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012.
4
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.免疫重建疗法还是持续免疫抑制用于治疗复发缓解型多发性硬化症活动期患者?一项叙述性综述。
Neurol Ther. 2020 Jun;9(1):55-66. doi: 10.1007/s40120-020-00187-3. Epub 2020 Apr 15.